This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

Navigation breadcrumbs

  1. Home
  2. Our priorities
  3. Cardiovascular health
  4. CVDACTION: Innovation to transform the prevention of cardiovascular disease

CVDACTION: Innovation to transform the prevention of cardiovascular disease

CVDACTION is a smart data tool developed by UCLPartners to help GP practices transform the prevention of cardiovascular disease.

Thousands of avoidable heart attacks and strokes would be prevented every year if more patients with high risk conditions like blood pressure, cholesterol, diabetes and chronic kidney disease received NICE recommended treatments.

CVDACTION makes it much easier for clinicians in real world primary care to spot patients who are high risk and undertreated so that their care can be rapidly optimised.

CVDACTION has been successfully trialled in 10 demonstrator sites in London covering a population of 500,000 people. The evaluation report is expected in early 2024.

Dr Matt Kearney is leading further development of CVDACTION. Across London and UCLPartners’ geography, Matt will provide this leadership through his role as Senior Advisor at UCLPartners. To scale CVDACTION beyond this area, Matt has established at spin-out company called Into-Action.Health

For more information

Please visit and contact Into-Action.Health.